{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-007007","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.152167+00:00","generated_at":"2026-05-16T11:14:22.281686+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acrivon reports positive ACR-368 Phase 2b data in serous EC; ACR-2316 shows tumor shrinkage in Phase 1","bullets":["ACR-368 Phase 2b: 39% ORR overall; in serous EC ≤2 prior lines, cORR 52% (N=23) and 67% in BM+ (N=12). Arm 3 expanding to EU, enrollment complete Q4 2026.","ACR-2316 Phase 1: 33 patients dosed; tumor shrinkage in 9/20 evaluable; confirmed PR in EC, unconfirmed PRs in SCLC and sqNSCLC. Two weekly schedules set.","ACR-6840, a potential first-in-class CDK11 inhibitor, nominated as development candidate; IND submission planned for Q4 2026.","Preliminary cash, cash equivalents and investments ~$119M as of Dec 31, 2025, expected to fund operations into Q2 2027.","Phase 3 confirmatory protocol for ACR-368 + anti-PD-1 submitted to FDA Nov 2025; global trial readiness expected mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-007007","json":"https://secwatch.observer/filing/0001193125-26-007007.json","markdown":"https://secwatch.observer/filing/0001193125-26-007007.md","text":"https://secwatch.observer/filing/0001193125-26-007007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526007007/0001193125-26-007007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526007007/acrv-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:14:22.281686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}